Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways.

The Journal of clinical investigation·2009
Same author

Cripto-1 overexpression is involved in the tumorigenesis of nasopharyngeal carcinoma.

BMC cancer·2009
Same author

Range of motion and orientation of the lumbar facet joints in vivo.

Spine·2009
Same author

[Silencing of COX-2 in nasopharyngeal carcinoma cells with a shRNAmir lentivirus vector].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2009
Same author

The risk of melamine-induced nephrolithiasis in young children starts at a lower intake level than recommended by the WHO.

Pediatric nephrology (Berlin, Germany)·2009
Same author

Adult scoliosis in patients over sixty-five years of age: outcomes of operative versus nonoperative treatment at a minimum two-year follow-up.

Spine·2009

Related Experiment Video

Updated: May 12, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Targeting MAPK pathway in melanoma therapy.

Yabin Cheng1, Guohong Zhang, Gang Li

  • 1Department of Dermatology and Skin Science, Research Pavilion, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada.

Cancer Metastasis Reviews
|April 16, 2013
PubMed
Summary
This summary is machine-generated.

New drugs targeting the mitogen-activated protein kinase (MAPK) pathway show promise for melanoma treatment. Combination therapies may overcome resistance and improve outcomes for patients with metastatic melanoma.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Related Experiment Videos

Last Updated: May 12, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The mitogen-activated protein kinase (MAPK) pathway is crucial in melanoma pathogenesis.
  • Targeted therapies, like BRAF inhibitors, have shown initial success in melanoma treatment.
  • Drug resistance and limited efficacy remain significant challenges in metastatic melanoma.

Purpose of the Study:

  • To review the therapeutic potential of targeting the MAPK signaling pathway in melanoma.
  • To summarize existing MAPK-inhibiting drugs for melanoma therapy.
  • To discuss combination treatment strategies to overcome drug resistance.

Main Methods:

  • Literature review of studies on MAPK pathway in melanoma.
  • Analysis of clinical trial data for MAPK inhibitors.
  • Evaluation of molecular mechanisms of drug resistance.

Main Results:

  • Targeting the MAPK pathway has yielded significant clinical responses in melanoma.
  • Selective BRAF and MEK inhibitors improve survival but face resistance issues.
  • Ongoing research focuses on overcoming resistance and improving treatment efficacy.

Conclusions:

  • Targeting the MAPK pathway is a validated strategy in melanoma therapy.
  • Combination therapies hold promise for overcoming resistance and improving patient prognosis.
  • Further investigation into novel small molecule inhibitors and combination treatments is warranted.